NewAmsterdam Pharma (NAMS) Expected to Announce Earnings on Wednesday

NewAmsterdam Pharma (NASDAQ:NAMS) will likely be posting its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect NewAmsterdam Pharma to post earnings of ($0.48) per share for the quarter.

NewAmsterdam Pharma Stock Performance

NewAmsterdam Pharma stock opened at $18.57 on Monday. NewAmsterdam Pharma has a twelve month low of $15.19 and a twelve month high of $27.29. The stock’s 50 day moving average is $23.17 and its 200 day moving average is $20.24.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, major shareholder Nap B.V. Forgrowth sold 100,728 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $26.10, for a total transaction of $2,629,000.80. Following the transaction, the insider now owns 10,908,502 shares in the company, valued at $284,711,902.20. This represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 404,927 shares of company stock valued at $10,390,787. 19.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

NAMS has been the topic of several research reports. Scotiabank raised their target price on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a report on Wednesday, December 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. HC Wainwright reissued a “buy” rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, NewAmsterdam Pharma currently has a consensus rating of “Buy” and a consensus price target of $41.60.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.